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Abstract
Background: Systemic autoinflammatory diseases (SAIDs) represent a growing number of monogenic, polygenic or
multifactorial disorders that are often difficult to diagnose.
Case presentation: Here we report a patient who was initially erroneously diagnosed and treated for SAID. Symptoms
consisted of recurrent fever, erythematous and/or blistering skin lesions, angioedema, susceptibility to bleeding, external
ear infections and reversible anisocoria in the absence of laboratory evidence of systemic inflammation. After two and a
half years of extensive diagnostic work-up and multiple empirical therapies, a final diagnosis of Munchausen by proxy
syndrome (MBPS) was established.
Conclusions: The diagnosis of SAID needs to be carefully reassessed if measurable systemic inflammation is missing, and
MBPS should be included in the differential diagnosis.
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Background
Systemic autoinflammatory diseases (SAIDs) comprise
of genetically defined conditions as well as disorders
of unknown pathogenesis. Examples of monogenic
SAIDs are Familial Mediterranean fever (FMF), cryo-
pyrin associated periodic syndromes (CAPS), mevalonate
kinase (MVK) deficiency and tumor necrosis factor recep-
tor associated periodic syndrome (TRAPS). In cases
where a specific diagnosis cannot be achieved, an
undifferentiated SAID is assumed. In contrast to
autoimmune diseases, SAIDs are driven by uncon-
trolled activation of the innate immune system [1, 2].
Typical clinical features include flares of recurrent
inflammation, fever, skin rash, arthritis, serositis and
organ involvement (e.g. skin, eyes, kidney). The clin-
ical presentation of these disorders overlaps to a cer-
tain degree, complicating and delaying their diagnosis.
Moreover, co-factors responsible for genotype-phenotype
variations are hard to identify, which can delay diagnosis
further [3].
Munchausen by proxy syndrome (MBPS) in chil-
dren, first described in 1977 by Meadow, refers to a
fabricated or induced illness [4, 5]. Alternative terms
for MBPS include factitious disorder by proxy or
medical child abuse. Regardless of the nomenclature,
MBPS is defined as harm carried out by a caregiver,
usually the mother, where a medical condition is ex-
aggerated, fabricated or induced [6]. Perpetrators
often have medical knowledge or ties to the medical
sector, may suffer from somatoform or factitious dis-
ease or personality disorders, or intend to gain social
attention or raise money for personal use [5]. MBPS
can be seen as a variant of battered child syndrome
(BCS). While BCS is an important cause of overall
paediatric morbidity and mortality with more than
650 thousand victims per year in the US, MBPS is* Correspondence: helmut.wittkowski@ukmuenster.de
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actually a rare entity with an annual incidence of ap-
proximately 0.5/100.000 in children younger than 16
years, though it is likely to be underreported [5, 7].
The spectrum of systemic involvement with which
MBPS may present is very broad and includes dermato-
logic, endocrine, gastrointestinal, hematologic, neurologic,
metabolic, infectious or rheumatologic symptoms and
fever.
Case presentation
We report the case of a 3 year old Caucasian boy who first
developed erythematous patches distributed over the
whole body at the age of 5 months (Fig. 1). A skin biopsy
was performed, showing faint polymorphonuclear gran-
ulocytic infiltrates; a histopathologic diagnosis of probable
autoinflammatory skin disease was made, which prompted
further diagnostic evaluations into SAIDs (s. Table 1). At 8
months of age, macroscopic haematuria, bloody diarrhoea
and epistaxis were reported by the mother. Shortly after,
recurrent episodes of fever up to 39.5 °C, 1–3 days
duration, were reported to be occurring every 2 weeks,
accompanied by an increase in erythematous skin lesions.
From the age of 12 months, ulcerative skin lesions
developing on previously intact skin primarily on the
extremities, a sudden-onset unilateral facial swelling and
transient anisocoria were seen (Fig. 1). Deep skin defects
developed after medical interventions such as bone
marrow aspiration or immunizations, which were interpreted
as representing a pathergy phenomenon. Subsequently, from
the age of 18 months, palmoplantar bullous skin lesions
occurred with rapid detachment of epidermal layers. One
skin lesion on the foot healed with scar formation.
The boy was the youngest of several siblings of a
family where both parents were part of the household
and did not have connections to the health care sector,
and who had no apparent psychiatric abnormalities.
A diagnosis of SAID was one of the first diagnoses
suspected, and was first proposed by the dermatologists,
as fever and skin symptoms are typical findings for these
entities. However, extensive testing yielded negative
results (Table 1). Autoimmune diseases and primary







Fig. 1 Evolution of symptoms according to age of life (in months). 5 months: Initial symptoms were erythematous skin lesions distributed over the whole
body (a–c). 8 months: Macrohaematuria, epistaxis and bloody diarrhoea were reported. 9 months: Fever episodes every second week. 12
months: Deep skin lesions with excoriation and ulcerations (d). Anisocoria (g) and unilateral facial swelling with sudden occurrence and transient (h).
16 months: deep ulcerating or necrotizing skin lesions with impaired heeling at bone marrow puncture site (e) or vaccination sites (f). 18 months:
bullous skin lesions occurred with sudden detachment of epidermal layers with predominantly palmar and plantar localisation (i). Blisters healed
without scarring usually after 2 weeks (j)
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Primary dermatologic disorders such as congenital or ac-
quired epidermolysis bullosa, bullous pemphigoid diseases
and other blistering skin diseases were ruled out by skin
biopsy. In total, six skin biopsies were performed over a
time span of 2 years. All biopsies showed faint perivascular
lymphocytic infiltrates associated with rare infiltrates of
polymorphonuclear granulocytes, possibly caused by mech-
anical or medical irritation of the skin. Several imaging
studies were performed including abdominal ultrasound,
brain MRI and echocardiography, all with normal re-
sults. Eye exams did not show any inflammatory
changes and an underlying cause for the episodic
mydriasis was not seen. Metabolic diseases were also
ruled out by extensive testing. Experts for childhood
metabolic diseases speculated on the presence of a
leukotriene-associated disorder, but there was no spe-
cific evidence to support this suggestion.
Due to suspecting a monogenic SAID like TRAPS or
an undifferentiated SAID throughout the disease course,
several treatments were implemented sequentially or in
combination, including prednisolone up to 2 mg/kg/d,
azathioprine (4 months of therapy), dapsone (3 months
of therapy), anakinra, ibuprofen and/or hydroxychloro-
quine. However, most of the signs and symptoms
described above persisted or recurred during treatment.
Subsequently, clinical investigations shifted increas-
ingly to the search for external and/or toxic factors.
Contaminants in the household were considered and
actively investigated, and screening for heavy metal
poisoning was pursued. In total five hospital admissions
for diagnostic purposes took place.
As the extensive work-up performed continued to
yield only negative results, it became increasingly appar-
ent that intrinsic disease was unlikely and MBPS was
suspected. However, during a 3-week hospital stay with
intensified surveillance, no maternal interference, that
might explain the patient’s signs and symptoms was
observed, symptoms remained the same. During this
time two findings in particular aroused suspicion, (1) re-
versible unilateral (otherwise unexplainable) mydriasis,
not reactive to topical application of pilocarpine 1% and
(2) the sudden appearance of bullous skin lesions in
previously intact skin. A North American expert panel
on child abuse was consulted by telephone conference
and it was felt that this case was highly suspicious for
MBPS. Ultimately, both parents were confronted with
the probable diagnosis with participation of the youth
welfare service and an attending psychiatrist. As the
mother was the person most consistently involved in the
care of the child and was always present during hospital
stays, we suspected her rather than the father to be the
perpetrator. The mother and patient were separated im-
mediately and the patient was admitted together with
his father. Within 2 weeks all signs and symptoms of
disease resolved.
In the meantime, the parents had contacted the police
to report, that a crime had been committed by an un-
known perpetrator. After 6 weeks of hospitalization, the
patient’s mother confessed in writing to having
performed multiple actions that resulted in different
signs and symptoms. These actions ranged from (1)
erroneous reporting (fever; medication not given), to (2)
interference of specimens (blood in urine/diaper;
manipulation of thermometer), and (3) induction of symp-
toms (mechanical irritation; application of capsaicin,
anti-wart patches, mydriatic eye drops and saliva/stool
application to induce skin infection) (Table 2).
Retrospectively, the primary care pediatrician reported
abnormally frequent visits of the mother with her son to
his medical practice, with up to 12 visits a month, pos-
sibly indicating secondary gain for the mother. However,
Table 1 Diagnostic testing with normal results
Autoinflammation/Autoimmunity
• Acute phase reaction proteins (CRP, SAA), Erythrocyte-Sedimentation
Rate (ESR), phagocyte-specific S100-proteins
• Sanger sequencing of the following genes: NLRP3 (CAPS), TNFRSF1a
(TRAPS), MVK (HIDS), MEFV (FMF), PSTPIP1 (PAPA)
• Antinuclear-antibodies (ANA), anti-dsDNA, antineutrophil cytoplasmic
antibodies (ANCA)
Immunodeficiency
• Complement system tests (AP 50, CH 50, C3 and C4)
• IgG, IgM, IgA, IgG-subclasses, lymphocyte subpopulations, vaccination
titers, T-cell proliferation, in vitro granulocyte respiratory burst, in vitro
granulocyte phagocytosis, maternal chimerism
• Bone marrow aspiration
Dermatologic conditions
• Skin biopsies on six occasions showing mild neutrophil infiltration
• Testing for epidermolysis bullosa, epidermolysis bullosa aquisita,
pemphigoid
Intoxications
• Intensive interview with family for identification of accidental contaminants
(plants, detergents, dyes, insecticides, mercury exposure etc.) in
their household and evaluation by public health department.
• Target-oriented tracing for contaminants in the private house of the
family by the local health authority
• Investigation of patient material for contaminants (e.g. urine for heavy
metals)
Miscellaneous
• Ultrasonography of abdomen and lymph nodes, cranial MRI on two
occasions, echocardiography
• Diagnostic hospitalisation for surveillance of suspicious activity of the
family (10 months of age; 32 months of age)
• Extensive ophthalmologic investigations for eye inflammation and
reasons for anisocoria
Abbreviations: CAPS cryopyrin-associated periodic syndrome, CRP C-reactive
protein, FMF familial mediterranean fever, HIDS hyper-IgD syndrome, PAPA
pyogenic arthritis, pyoderma gangrenosum, acne, SAA serum amyloid A, TRAPS
tumor necrosis factor receptor-associated periodic syndrome
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no medical opinions beyond our center were accessed by
the family. At the age of 3 years, a diagnosis of MBPS
was firmly established with the evidence that separating
mother and child led to spontaneous resolution of all
disease symptoms and signs, along with the confession
from the mother.
Review of the literature
MBPS is a potentially life-threatening disorder with up
to 6% mortality. The clinical spectrum ranges from a
caregiver displaying too much concern regarding minor
symptoms, to a caregiver inducing illness with possible
major impact on the child’s physical and mental health
[8]. Factitious disorders in adolescents and adults have
been described to simulate rheumatic conditions such as
panniculitis or lupus [9, 10]. Such observations have
been made in patients treated for lupus-like disease who
were for example positive for ANA (an unspecific find-
ing) and also had the appearance of renal symptoms
(due to manipulated urine), rash (which was fabricated)
along with reported photosensitivity or arthritis [10].
Nonetheless, a search of PubMed with the terms
“Munchausen Syndrome by Proxy” and “Rheumatology”,
“Autoinflammation”, “Autoimmunity”, “Arthritis” or
“Lupus” retrieved no results for original data.
In contrast, fever was reported as early as 1987 as be-
longing to one of the most frequent symptoms of MBPS
detected in 10% of 117 cases along with bleeding (44%),
seizures (42%), CNS depression (19%), apnoea (15%),
diarrhoea (11%) and vomiting (10%) [11]. Fever in MBPS
can result from the induced infections, but is also falsely
reported or fabricated via the manipulation of thermom-
eters, physically generated hyperthermia, or falsified on
charts [11]. Fever in MBPS has also been chemically in-
duced by the deliberate administration of diazoxide,
alimemazine, ipecac, or mercury poisoning [12–15].
MBPS mimicking rheumatic conditions is probably
uncommon but may be underreported. A case-report
from 1987 describes a 7-year old girl, who presented
with fever of unknown origin and then repeatedly
presented with remitting fever over a period of 6 years
and was transiently treated as SJIA. Additional observa-
tions were asthma, chronic purulent otitis media, and
unilateral mydriasis. Finally, severe diarrhoea and
vomiting found to be due to theophylline intoxication,
were the last symptoms before discovery of the
underlying condition [16].
We are aware of another MBPS case, which was first
erroneously treated for hemophagocytic lymphohistiocy-
tosis (HLH), another rare immunologic condition associ-
ated with recurrent fevers [17]. However, the reverse has
also been reported, with a case of an SAID, later identi-
fied as MVK deficiency, being mistaken as MBPS [18].
Discussion and conclusions
The mean time from the onset of symptoms to the time
of diagnosis in MBPS is around 15 months [11]. Recog-
nition of MBPS early in the disease course is difficult
and, as in this case, can be delayed for several reasons.
Importantly, clinical and skin biopsy findings were
misinterpreted. Therefore in this case, the popular
phrase coined by Maslow “if all you have is a hammer,
everything looks like a nail” applies. We were, in retro-
spect, focussing for too long on identifying a unifying
inflammatory condition for this patient’s disease process.
Even though the maternal actions (Table 2) have been
described in the past in the context of MBPS, especially
with fever as a key finding, the multitude of actions in
this case was distracting [11, 19–21].
The importance of a multidisciplinary approach must
be emphasized. In our case, the diagnosis became
obvious during case conferences involving general
paediatric, dermatology, immunology, rheumatology, oph-
thalmology, pharmacology/toxicology, psychiatrics, and
forensic medicine specialists. Specific observations that
led to the diagnosis included the absence of measurable
inflammation even during episodes of fever, unilateral
recurrent (otherwise unexplainable) mydriasis and the
sudden occurrence of blisters on previously intact skin.
These findings were felt to be unexplainable by any
mechanism other than by MBPS.
While fever is a frequent sign associated with MBPS,
there are no previous reports or case series on patients
with MBPS who had been mistaken as SAIDs. On the
other hand, since SAIDs comprise a heterogeneous
group of inflammatory disorders that were collectively
defined only around 15 years ago, an under diagnosis of
Table 2 Symptoms and probable causative action of the mother
Symptom Probable etiology
erythematous skin lesions rubbing and mechanical irritation;








deceptive reporting by the mother
ulcerations and excoriations extensive rubbing and mechanical
irritation
ulcerations after vaccinations
and bone marrow puncture
mechanical manipulation
palmar and plantar bullous
skin lesions
administration of anti-warts patches
angioedema in face and
dorsum of hands and feet
mechanical manipulation; presumably
application of capsaicin containing
ointments
anisocoria administration of mydriatic eye drops
Infections of the acoustic
meatus
administration of salivate or diaper
content
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SAIDs is also likely [1]. It remains a clinical dilemma
that fever may be a sign of serious disease processes
including SAIDs, but, as discussed above, can also be
produced factitiously by various means. Therefore,
critical evaluation and scrutiny of recurrent fevers in
children is mandatory. A high index of suspicion both
for SAID and MBPS is needed to unravel cases with
atypical combinations of symptoms and a poor response
to anti-inflammatory therapies.
In conclusion, we describe for the first time a clinical
case of MBPS specifically mimicking SAIDs, which
resulted in a delayed diagnosis. We recommend MBPS
be added to the differential diagnosis of SAIDs. Incon-
sistent clinical findings, for example lack of measurable
inflammation during fever, should prompt suspicion for
diagnosis of MBPS.
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